UK Markets closed

Global Veterinary Oncology Market to Reach $495.1 Million by 2027

ReportLinker
ReportLinker

In the changed post COVID-19 business landscape, the global market for Veterinary Oncology estimated at US$216. 8 Million in the year 2020, is projected to reach a revised size of US$495. 1 Million by 2027, growing at a CAGR of 12.

New York, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Veterinary Oncology Industry" - https://www.reportlinker.com/p06033237/?utm_source=GNW
5% over the analysis period 2020-2027. Chemotherapy, one of the segments analyzed in the report, is projected to record a 13.7% CAGR and reach US$162 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Radiology segment is readjusted to a revised 11.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $59.1 Million, While China is Forecast to Grow at 16.2% CAGR

The Veterinary Oncology market in the U.S. is estimated at US$59.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$104.9 Million by the year 2027 trailing a CAGR of 16.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 11% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$70.5 Million by the year 2027.



Immunotherapy Segment to Record 12.9% CAGR

In the global Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 12.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$32.6 Million in the year 2020 will reach a projected size of US$72.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 14.5% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -
Accuray Incorporated
Boehringer Ingelheim International GmbH
Elanco
Karyopharm Therapeutics, Inc.
Morphogenesis, Inc.
Nippon Zenyaku Kogyo Co., Ltd.
One Health
PetCure Oncology
Regeneus Ltd.
Varian Medical System, Inc.


Read the full report: https://www.reportlinker.com/p06033237/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Veterinary Oncology - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Veterinary Oncology by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Veterinary Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Veterinary Oncology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Radiology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Radiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Radiology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Chemotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Surgery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Surgery by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Surgery by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Other Therapies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Therapies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Other Therapies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Canine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Canine by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Canine by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Feline by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Feline by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Feline by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Lymphoma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Lymphoma by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Lymphoma by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for Mast
Cell Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Mast Cell Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Mast Cell Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Mammary & Squamous Cell Cancer by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Mammary & Squamous Cell
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Mammary & Squamous Cell
Cancer by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

Table 34: World Recent Past, Current & Future Analysis for
Other Cancer Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Cancer Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cancer Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 37: World Veterinary Oncology Market Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2027

III. MARKET ANALYSIS

UNITED STATES
Veterinary Oncology Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 38: USA Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 39: USA Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 40: USA 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 41: USA Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 42: USA Historic Review for Veterinary Oncology by Animal
Type - Canine and Feline Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 43: USA 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 44: USA Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 45: USA Historic Review for Veterinary Oncology by Cancer
Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell
Cancer and Other Cancer Types Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 46: USA 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

CANADA
Table 47: Canada Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 48: Canada Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 49: Canada 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 50: Canada Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 51: Canada Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 52: Canada 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 53: Canada Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 54: Canada Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 55: Canada 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

JAPAN
Veterinary Oncology Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 56: Japan Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 57: Japan Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 58: Japan 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 59: Japan Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 60: Japan Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 61: Japan 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 62: Japan Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 63: Japan Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 64: Japan 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

CHINA
Veterinary Oncology Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 65: China Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 66: China Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 67: China 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 68: China Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 69: China Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 70: China 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 71: China Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 72: China Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 73: China 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

EUROPE
Veterinary Oncology Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 74: Europe Recent Past, Current & Future Analysis for
Veterinary Oncology by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 75: Europe Historic Review for Veterinary Oncology by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 76: Europe 15-Year Perspective for Veterinary Oncology by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

Table 77: Europe Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 78: Europe Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 79: Europe 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 80: Europe Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 81: Europe Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 82: Europe 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 83: Europe Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 84: Europe Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 85: Europe 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

FRANCE
Veterinary Oncology Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 86: France Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 87: France Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 88: France 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 89: France Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 90: France Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 91: France 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 92: France Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 93: France Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 94: France 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

GERMANY
Veterinary Oncology Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 95: Germany Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 96: Germany Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 97: Germany 15-Year Perspective for Veterinary Oncology
by Therapy - Percentage Breakdown of Value Sales for
Chemotherapy, Radiology, Immunotherapy, Surgery and Other
Therapies for the Years 2012, 2021 & 2027

Table 98: Germany Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 99: Germany Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 100: Germany 15-Year Perspective for Veterinary Oncology
by Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 101: Germany Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 102: Germany Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 103: Germany 15-Year Perspective for Veterinary Oncology
by Cancer Type - Percentage Breakdown of Value Sales for
Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and
Other Cancer Types for the Years 2012, 2021 & 2027

ITALY
Table 104: Italy Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 105: Italy Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 106: Italy 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 107: Italy Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 108: Italy Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 109: Italy 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 110: Italy Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 111: Italy Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 112: Italy 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

UNITED KINGDOM
Veterinary Oncology Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 113: UK Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 114: UK Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 115: UK 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 116: UK Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 117: UK Historic Review for Veterinary Oncology by Animal
Type - Canine and Feline Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 118: UK 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 119: UK Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 120: UK Historic Review for Veterinary Oncology by Cancer
Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell
Cancer and Other Cancer Types Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 121: UK 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2021 & 2027

SPAIN
Table 122: Spain Recent Past, Current & Future Analysis for
Veterinary Oncology by Therapy - Chemotherapy, Radiology,
Immunotherapy, Surgery and Other Therapies - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 123: Spain Historic Review for Veterinary Oncology by
Therapy - Chemotherapy, Radiology, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 124: Spain 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Chemotherapy,
Radiology, Immunotherapy, Surgery and Other Therapies for the
Years 2012, 2021 & 2027

Table 125: Spain Recent Past, Current & Future Analysis for
Veterinary Oncology by Animal Type - Canine and Feline -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 126: Spain Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 127: Spain 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2021 & 2027

Table 128: Spain Recent Past, Current & Future Analysis for
Veterinary Oncology by Cancer Type - Lymphoma, Mast Cell
Cancer, Mammary & Squamous Cell Cancer and Other Cancer Types -
Independent Analysis of Annual Sales in US$ Thousand for the

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033237/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001